Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing
Market News Market Pulse Stocks News ETF News Crypto News

24/7 Market News and NeOnc Technology

Contributing Author

Recent Articles by 24/7 Market News and NeOnc Technology

Nov-02
NeOnc Is Putting Two Brain Cancer Programs on the Global Stage NTHI -5.83% GlobeNewswire
Oct-30
NeOnc's Ambitious Brain Cancer Plans are Setting the Stage NTHI GlobeNewswire
Oct-26
NeOnc Targets Major Brain Cancer Trial Expansion with 500 Patients Across 30 Hospitals in Three Countries NTHI -13.76% GlobeNewswire
Oct-23
NeOnc Breaks Through Key Levels, as Brain-Cancer Stock's Catalysts Continue NTHI +10.85% GlobeNewswire
Oct-22
NeOnc Heads to Fox Business as Brain Cancer Milestones Put Its Mission in the Spotlight NTHI GlobeNewswire
Oct-21
NeOnc Deepens Abu Dhabi Research Ties as Its Brain Cancer Story Moves Forward NTHI GlobeNewswire
Oct-20
Forget the Ugly Sweaters and Ugly Charts, NeOnc is Ready for Catalyst Season NTHI GlobeNewswire
Oct-16
NeOnc's Boldest Test Yet: Child's Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone NTHI GlobeNewswire
Oct-15
UAE Banking Heavyweight Joins NeOnc as Global Brain-Cancer Drug Development Advances NTHI GlobeNewswire
Oct-14
NeOnc Strengthens Boardroom Firepower as Abu Dhabi Opens a New Path for Brain Cancer Drug Development NTHI GlobeNewswire
Oct-07
NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer NTHI -9.36% GlobeNewswire
Sep-28
Powerful NeOnc Brain Cancer Pipeline Advances NTHI GlobeNewswire
Sep-24
NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst NTHI GlobeNewswire
Sep-22
NeOnc's Delivery may Finally Change the Equation for Brain Cancer's Next Frontier NTHI NTHI -6.67% GlobeNewswire
Sep-21
NeOnc Charting New Nasal Route to Treating Brain Cancer NTHI GlobeNewswire
Sep-17
NeOnc Eliminates Major Dilution Risk as Clinical Story Accelerates NTHI +14.05% GlobeNewswire
Sep-16
NeOnc's $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA NTHI -9.67% GlobeNewswire
Sep-14
Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test NTHI GlobeNewswire
Sep-09
NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data NTHI -11.06% GlobeNewswire
Sep-08
NeOnc' Phase 2 Data Could Put Cancer on the Ropes NTHI -19.09% GlobeNewswire
Aug-28
NeOnc's Phase 2A Success Could Set the Stage for Something Much Bigger NTHI GlobeNewswire
Aug-26
NeOnc's Clinical Story Is Now the Main Event NTHI GlobeNewswire
Aug-18
NeOnc Technologies- Talk Is Cheap, Insider Buying Isn't NTHI +12.63% GlobeNewswire
Aug-17
NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results NTHI +16.35% GlobeNewswire
Aug-13
The Nose Knows: Why NeOnc's Patent Portfolio Could Make NTHI More Than a One-Drug Biotech NTHI -7.23% NTHI +31.46% GlobeNewswire
Aug-10
NeOnc Heads into a High-Stakes Week as Highly Anticipated NEO100 Phase 2a Data Readout Nears NTHI GlobeNewswire
Jun-24
NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum NTHI GlobeNewswire
Jun-16
Brain Cancer Innovator NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND NTHI +14.86% NTHI -7.14% GlobeNewswire
May-29
The Next Great AI Revolution May Be Drug Delivery NTHI GlobeNewswire
May-19
NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones NTHI GlobeNewswire
May-07
Biotech's Next Wave May Already be in Motion NTHI +22.22% GlobeNewswire
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)